What Is Thrombotic Microangiopathy Causes Types Treatment?

Thrombotic microangiopathy, often shortened to TMA, is a pattern of injury to the smallest blood vessels in the body. It happens when tiny clots form inside capillaries and arterioles, the body’s narrowest blood vessels, and red blood cells get damaged as they squeeze past those clots. The result is a familiar trio of problems: red blood cells break apart (hemolysis), platelets get used up (thrombocytopenia), and organs — especially the kidneys and brain — start to suffer from reduced blood flow.

TMA is not one disease. It is a shared injury pattern that several different conditions can produce, and the cause matters enormously because the treatments are completely different. Some forms are medical emergencies that can be fatal within days if not recognized. Others are tied to pregnancy, medications, transplants, or autoimmune disease. Knowing what is driving the TMA is the single most important step in managing it.

What Is Thrombotic Microangiopathy and How Does It Damage Blood Vessels?

The damage starts in the endothelial lining — the single layer of cells that coats the inside of every blood vessel. When those cells are injured, they stop doing their normal job of keeping blood flowing smoothly. Instead, platelets clump together and strands of a protein called von Willebrand factor build up, forming microscopic clots inside vessels that are often only slightly wider than a red blood cell.

Red blood cells passing through these narrowed, clot-filled vessels get physically shredded. On a blood smear, this shows up as schistocytes — fragmented red blood cells that look like helmets or triangles. That finding, combined with a low platelet count and signs of organ damage, is the classic signature of TMA.

The clots also block blood flow. The kidneys are especially vulnerable because they filter enormous volumes of blood through dense networks of tiny vessels. The brain, heart, and digestive tract can be affected too. This is why TMA often shows up first as kidney failure, confusion, seizures, or abdominal pain — not as an obvious bleeding problem.

One detail worth understanding: TMA is defined by its appearance under the microscope and its lab findings, not by a single cause. Two patients with nearly identical blood tests can have completely different diseases and need completely different treatments.

What Causes Thrombotic Microangiopathy?

The causes fall into a handful of broad categories. The most important distinction is between TMA caused by a problem with a specific enzyme that cuts von Willebrand factor, and TMA caused by damage to the endothelial lining from other sources.

The first group centers on ADAMTS13, a blood enzyme that normally trims large von Willebrand factor multimers so they do not cause clots. When ADAMTS13 activity drops severely — usually because autoantibodies attack it — those oversized multimers accumulate and trigger widespread clotting. This is the mechanism behind immune-mediated thrombotic thrombocytopenic purpura, or TTP.

The second group is driven by endothelial injury from many directions:

• Complement dysregulation — an overactive immune protein cascade that attacks endothelial cells, the hallmark of atypical hemolytic uremic syndrome (aHUS)
• Shiga toxin — produced by certain E. coli strains, which causes typical (STEC-associated) hemolytic uremic syndrome, often after bloody diarrhea
• Pregnancy — conditions like preeclampsia, HELLP syndrome, and postpartum TMA
• Medications — some immunosuppressants, chemotherapy agents, and antiplatelet drugs have been linked to TMA
• Transplant — both stem cell and solid organ transplants can trigger TMA
• Autoimmune disease — lupus and scleroderma are known associations
• Infection and malignancy — including HIV and certain cancers
• Inherited complement mutations — genetic variants that predispose to aHUS

In practice, doctors often cannot pin down a single trigger. Some cases are labeled “secondary TMA” when a clear underlying condition is present, and that label guides treatment toward managing the underlying problem.

What Are the Main Types of TMA?

Clinicians generally group TMA into a few recognizable categories. The names can be confusing because they overlap, but the distinctions matter for treatment.

TTP and aHUS are the two forms most likely to be life-threatening without rapid treatment. STEC-HUS is more common in children and often follows a bout of bloody diarrhea. Secondary TMA is the most varied group and the hardest to generalize about.

What Are the Symptoms of Thrombotic Microangiopathy?

Symptoms reflect where the clots are forming and how much red blood cell destruction is happening. Early on, many people feel generally unwell — fatigue, weakness, and shortness of breath from anemia.

Because platelets are being consumed, bleeding and bruising can appear, though serious bleeding is less common than the clotting itself. Tiny purple spots called petechiae may show up on the skin.

Organ-specific symptoms are often the most telling:

• Kidneys — decreased urine output, swelling, dark or cola-colored urine from hemoglobin breakdown
• Brain — confusion, headache, seizures, stroke-like episodes, personality changes
• Heart — chest pain, shortness of breath, abnormal heart rhythms
• Digestive tract — abdominal pain, nausea, diarrhea, sometimes bloody

In TTP specifically, the classic combination of neurological symptoms and low platelets with hemolysis is a red flag. Fever can occur but is not always present. The absence of fever or neurological signs does not rule TTP out.

How Is TMA Diagnosed?

Diagnosis starts with blood tests. A complete blood count showing anemia and low platelets is often the first clue. A blood smear looking for schistocytes supports the diagnosis. Markers of hemolysis — elevated lactate dehydrogenase, low haptoglobin, elevated indirect bilirubin — point to red blood cell destruction.

Kidney function tests, including creatinine and urinalysis, reveal organ involvement. A Coombs test is typically negative, which helps distinguish TMA from autoimmune hemolytic anemia.

The critical test is ADAMTS13 activity. A level below roughly 10 percent strongly supports TTP. Because that result can take time to return, many clinicians start treatment for suspected TTP before the result is available — the risk of waiting is too high.

Complement testing, including genetic panels, may be ordered when aHUS is suspected. Stool testing for Shiga toxin is important if diarrhea is present. In some cases, a kidney biopsy is performed to confirm the pattern of injury, though it is not always necessary.

How Is Thrombotic Microangiopathy Treated?

Treatment depends entirely on the underlying cause. There is no single therapy that works for all TMA.

For suspected or confirmed TTP, plasma exchange is the standard of care. This procedure removes the autoantibodies and replaces the missing ADAMTS13 enzyme. It is typically started urgently and continued daily until platelet counts recover. Steroids are often given alongside it. A targeted drug called caplacizumab, which blocks the interaction between platelets and von Willebrand factor, has changed outcomes for immune-mediated TTP in recent years and is used in many centers.

For STEC-HUS, treatment is mainly supportive. Careful fluid and electrolyte management, blood pressure control, and dialysis if kidney failure develops are the mainstays. Antibiotics and antidiarrheal medications are generally avoided in this setting because some evidence suggests they may worsen the condition, though this remains an area of ongoing discussion. Plasma exchange is not typically helpful for STEC-HUS.

For aHUS, the treatment is a complement inhibitor — most commonly eculizumab or a related drug. These medications block the overactive complement cascade and have substantially changed the outlook for aHUS, which previously had a poor prognosis. They are not effective for TTP or STEC-HUS.

For secondary TMA, the priority is treating the underlying condition. That might mean stopping an offending medication, managing preeclampsia with delivery, treating an autoimmune disease, or addressing a transplant complication. Plasma exchange, steroids, and other therapies may be used depending on the situation, but the evidence for each is more limited than for TTP or aHUS.

Across all types, supportive care matters: blood pressure control, kidney support including dialysis when needed, and management of anemia. Some patients need long-term kidney follow-up even after the acute episode resolves.

What Is the Outlook for People With TMA?

Outcomes vary widely by type and by how quickly treatment starts. Untreated TTP has historically been fatal in a large majority of cases, which is why it is treated as an emergency. With prompt plasma exchange and modern therapy, survival has improved substantially, though relapses can occur and long-term neurological or kidney effects are possible.

STEC-HUS in children generally has a better prognosis than many people expect, with most recovering kidney function, though a minority develop long-term kidney problems and need monitoring. In adults, STEC-HUS tends to be more severe.

aHUS outcomes have improved considerably since complement inhibitors became available, but the disease can still cause permanent kidney damage, and some patients progress to end-stage kidney disease. Long-term follow-up is standard.

Secondary TMA outcomes depend heavily on the underlying cause and how reversible it is. There is no single prognosis that applies to all TMA, and any discussion of outlook should be specific to the individual case.